HF 2009: Relating to manufacturers and distributors of 340B drugs

What it does

This bill relates to manufacturers and distributors of 340B drugs. “340B drug”, “manufacturer”, and “distributor” are defined in the bill. The bill prohibits a manufacturer or distributor from, directly or indirectly, denying, restricting, or interfering with the acquisition of a 340B drug by a covered entity, or the delivery of a 340B drug to a contract pharmacy, unless otherwise prohibited by the United States department of health and human services.

House subcommittee · named January 14, 2026

• Rep. Brett Barker (R) · brett.barker@legis.iowa.gov
• Rep. Michael R. Bergan (R) · michael.bergan@legis.iowa.gov
• Rep. Ross Wilburn (D) · ross.wilburn@legis.iowa.gov

Lobbying · 8 for, 10 against

For: Iowa Chapter-American Academy of Pediatrics; Iowa Hospital Association; Iowa Integrated Health Planning and Advisory Council; Iowa Medical Society; Iowa Pharmacy Association; Iowa Primary Care Association; Mindspring Mental Health Alliance; United Way Quad Cities

Against: Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb Co.; Eli Lilly & Co.; GSK; Genentech, Inc., A Member of the Roche Group; Iowa Biotechnology Association; Merck Sharp & Dohme LLC; Novartis Services, Inc.; Novo Nordisk; Pharmaceutical Research and Manufacturers of America (PhRMA)

In plain words

1. January 13, 2026Filed in the House and sent to the Health and Human Services committee
2. January 14, 2026House subcommittee named: Barker, Bergan and Wilburn
3. January 21, 2026Subcommittee recommended passing it